Request for quotation Z3/5438/1 MRA Colistimethate Sodium – vials 20H, hydrolytic class I

In connection with the implementation of the project 2022/ABM/04/00016 – Development and development of a new pharmaceutical form of a medicinal product based on an approved active substance, containing the antibiotic colistimethate sodium used in the treatment of severe infections caused by gram-negative bacteria, Tarchomińskie Zakłady Farmaceutyczne POLFA S.A. invites you to submit offers for the subject of the contract specified below.

Detailed information regarding the proceedings can be found in the attached RFQ Z3_5438_1 – MRA Colistimethate Sodium – vials 20H, hydrolytic class I.

The project is financed from the state budget under a grant awarded by the Medical Research Agency.

More information: Tenders – TZF Polfa